{"filings":[{"id":490596,"accession_number":"0000883984-26-000031","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2026-05-18T16:35:44+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"ICU Medical shareholders approve simple majority voting, 25% special meeting right","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Charter amendments eliminating supermajority and allowing 25%-owner special meetings effective May 15, 2026.","All 7 director nominees elected; Deloitte & Touche ratified as auditor for FY2026.","Advisory vote on executive compensation passed with 21.2M for, 0.9M against.","Stockholder proposal for 10% special meeting right rejected: 9.0M for, 13.1M against.","Bylaws amended to implement procedural requirements for special meeting requests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99423,"accession_number":"0000883984-26-000028","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q1 GAAP net income $30.1M vs loss a year ago; organic revenue up 1%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP revenue $530.2M, down 12% YoY due to IV Solutions divestiture; non-GAAP organic revenue up 1%.","GAAP gross margin improved to 39% from 35%; gross profit $206.2M vs $210.1M.","GAAP diluted EPS $1.20 vs $(0.63) loss; adjusted diluted EPS $1.97 vs $1.72.","Adjusted EBITDA $98.7M vs $99.4M; company reiterates focus on innovation and operational efficiency.","Results reflect first full quarter without IV Solutions; management highlights margin expansion and cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":530225000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115412,"accession_number":"0000883984-26-000010","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2026-02-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ICU Medical extends Executive Severance Plan term to Dec 31, 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved amendment extending plan expiration from Dec 31, 2025 to Dec 31, 2028.","Amendment effective as of Dec 31, 2025; plan automatically terminates if no Change in Control occurs by new date.","Plan provides severance benefits to eligible executives upon a Change in Control; no other terms changed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115411,"accession_number":"0000883984-26-000007","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q4: revenue $540.7M (-14% YoY), GAAP loss $(0.64)/share, adj EPS $1.91","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Revenue $540.7M vs $629.8M in Q4 2024, down 14.1% YoY.","GAAP net loss $(15.7)M, or $(0.64) per diluted share, improving from $(23.8)M loss in Q4 2024.","Adjusted diluted EPS $1.91, down from $2.11; Adjusted EBITDA $98.2M vs $105.5M.","GAAP gross margin improved to 38% from 36%.","Fiscal 2026 guidance provided but numerical details not included in filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":2231262000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131826,"accession_number":"0000883984-25-000034","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q3 revenue down 8.8% YoY; adjusted EPS improves to $2.03","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $537M vs $589M YoY; GAAP net loss narrowed to $3.4M from $33M.","Adjusted diluted EPS $2.03 vs $1.59 YoY; adjusted EBITDA $105.9M vs $94.8M.","GAAP gross margin improved to 37% from 35% YoY.","Company updated fiscal year 2025 guidance; details in press release."],"consensus_eps_estimate":null,"consensus_eps_actual":0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":1690558000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148419,"accession_number":"0000883984-25-000029","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q2 revenue down 8% to $549M, but GAAP net income of $35.3M vs year-ago loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $548.9M vs $596.5M YoY; GAAP gross margin improved to 38% from 35%.","GAAP net income $35.3M ($1.43 diluted EPS) vs net loss of $(21.4M) ($(0.88) EPS) in Q2 2024.","Adjusted diluted EPS $2.10 vs $1.56 YoY; Adjusted EBITDA $100.3M vs $91.3M.","Fiscal 2025 guidance updated in the press release; specifics not provided in excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":1153568000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167208,"accession_number":"0000883984-25-000018","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ICU Medical shareholders approve stock plan amendment adding 2.15M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2011 Stock Incentive Plan, increasing share reserve by 2,150,000 to 8,515,510 shares.","All seven director nominees elected; Deloitte & Touche ratified as auditor for FY2025.","Advisory vote on executive compensation approved; shareholder simple majority voting proposal approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167207,"accession_number":"0000883984-25-000014","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q1 revenue up 7% to $605M; adjusted EPS $1.72 vs $0.96","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $604.7M, up 6.7% YoY from $566.7M.","GAAP net loss $(15.5)M ($0.63 loss per share) vs $(39.5)M ($1.63 loss) YoY.","Adjusted diluted EPS $1.72, up from $0.96 in Q1 2024.","Adjusted EBITDA $99.4M vs $78.8M YoY, a 26% increase.","GAAP gross margin expanded to 35% from 33% in prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":604702000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184566,"accession_number":"0000883984-25-000006","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q4 2024 revenue up 7% to $629.8M; adj. EPS $2.11 vs $1.57","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $629.8M (+7% YoY); GAAP gross margin improved to 36.1% from 29.2%.","GAAP net loss $(23.8)M ($(0.97)/share) vs $(17.1)M loss ($(0.71)) in Q4 2023.","Adjusted diluted EPS $2.11 vs $1.57 YoY; Adjusted EBITDA $105.5M vs $86.3M.","Company provided fiscal year 2025 guidance (detailed numbers not in excerpt)."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":2382046000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201131,"accession_number":"0000883984-24-000040","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q3 2024 revenue up 6.5% to $589.1M; GAAP net loss $33M, adj EPS $1.59","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $589.1M vs $553.3M YoY; GAAP gross margin improved to 34.8% from 33.2%.","GAAP net loss $(33.0)M ($1.35 per diluted share) vs net income $7.2M ($0.30) in Q3 2023.","Adjusted diluted EPS $1.59 vs $1.57 YoY; Adjusted EBITDA $94.8M vs $89.8M.","Company updated FY2024 guidance; specific guidance numbers not fully disclosed in excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":1752241000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201130,"accession_number":"0000883984-24-000032","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ICU Medical appoints Daniel Woolson as President, effective Sept. 30, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Woolson, 48, appointed President of ICU Medical, effective immediately on Sept. 30, 2024.","Woolson previously served as Corporate VP and General Manager - Infusion Systems since 2017.","Prior roles include President, Respiratory Solutions at Becton Dickinson (2015-2016) and VP/GM at CareFusion.","No departure of current CEO or other officers was announced in connection with this appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217157,"accession_number":"0000883984-24-000028","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q2 revenue up 8.6% to $596.5M but GAAP net loss widens to $21.4M; adjusted EPS down to $1.56","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Revenue $596.5M up 8.6% YoY from $549.3M; GAAP gross margin 35% unchanged.","GAAP net loss $(21.4)M ($0.88 loss per diluted share) vs $(9.9)M loss ($0.41) in Q2 2023.","Adjusted diluted EPS $1.56 vs $1.88 YoY; adjusted EBITDA $91.3M down from $98.1M.","Fiscal 2024 guidance updated; details not included in this excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":1163110000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236929,"accession_number":"0000883984-24-000018","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ICU Medical holds 2024 Annual Meeting; all director nominees elected, auditor ratified, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected: Vivek Jain, David C. Greenberg, Elisha W. Finney, David F. Hoffmeister, Donald M. Abbey, Laurie Hernandez, Kolleen T. Kennedy.","Ratification of Deloitte & Touche as independent auditor for FY 2024 approved with 22,484,283 votes for, 222,466 against.","Advisory vote on named executive officer compensation approved with 20,673,543 votes for, 824,221 against.","Broker non-votes totaled 1,202,538 on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236928,"accession_number":"0000883984-24-000014","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q1 GAAP EPS $(1.63) loss, revenue flat at $566.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $566.7M, down slightly from $568.6M YoY; GAAP net loss $(39.5)M vs $(9.8)M.","GAAP diluted EPS loss $(1.63) compared to loss $(0.41) in prior year.","Adjusted diluted EPS $0.96, down from $1.74; Adjusted EBITDA $78.8M vs $102.0M.","No forward guidance provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":566655000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254531,"accession_number":"0000883984-24-000007","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ICU Medical director William Seeger resigns immediately ahead of Smiths board retirement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Seeger resigned as director and Audit Committee member effective Feb. 28, 2024.","Resignation due to his planned retirement from Smiths Group plc board on May 31, 2024.","No disagreement with ICU Medical or its operations, policies, or practices.","Smiths retains right to designate a replacement as long as it holds ≥5% of ICUI common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254530,"accession_number":"0000883984-24-000004","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q4 revenue up slightly but net loss widens; provides FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Revenue $587.9M in Q4 2023, up 1.7% YoY from $578.0M.","GAAP net loss $17.1M ($0.71/share) widened from $15.5M loss ($0.65/share) in Q4 2022.","Adjusted EBITDA $86.3M vs $96.4M YoY; adjusted EPS $1.57 vs $1.60.","Gross margin slipped to 29% from 30%; gross profit $171.6M vs $174.9M.","Company issued FY2024 guidance (not detailed in excerpt)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":2259126000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272001,"accession_number":"0000883984-23-000037","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical reports Q3 revenue down 7.5% to $553.3M; GAAP EPS $0.30 vs loss, adjusted EPS $1.57","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $553.3M vs $597.9M YoY (-7.5%), GAAP net income $7.2M ($0.30 diluted) vs loss of $13.2M.","Adjusted diluted EPS $1.57 vs $1.75 YoY; adjusted EBITDA $89.8M vs $92.6M.","GAAP gross margin improved to 33% from 31% in Q3 2022.","No forward guidance provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":1671270000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272000,"accession_number":"0000883984-23-000034","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"ICU Medical amends bylaws to adopt universal proxy rules and exclusive forum provisions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendments effective Oct 30, 2023, address universal proxy rules under Rule 14a-19.","Enhanced disclosure requirements for stockholder nominations and proposals at meetings.","Requires proxy cards soliciting for non-Board nominees to be a color other than white.","Adopts exclusive forum for Delaware Chancery Court for certain actions and federal courts for Securities Act claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288848,"accession_number":"0000883984-23-000029","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q2 revenue $549.3M (-2% YoY); adjusted EPS $1.88 vs $1.37; narrows FY23 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $549.3M vs $561.0M YoY; GAAP gross margin improved to 35% from 30%.","GAAP net loss $(9.9)M ($(0.41)/share) vs $(7.5)M ($(0.31)/share) YoY.","Adjusted diluted EPS $1.88 vs $1.37; adjusted EBITDA $98.1M vs $84.7M.","Company narrows fiscal year 2023 guidance ranges for revenue and adjusted EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":1117959000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309532,"accession_number":"0000883984-23-000024","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"ICU Medical stockholders approve 2.2M share increase in 2011 Stock Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share reserve increased by 2,186,000 to 6,365,510; plan extended through March 14, 2033.","All nine director nominees elected; Deloitte & Touche ratified as auditor for FY2023.","Advisory say-on-pay approved (96.6% of votes cast); frequency set at one year.","Plan adds clawback policy and limited vesting exceptions for director and substitute awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309531,"accession_number":"0000883984-23-000020","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q1 revenue up 5% to $568.6M; GAAP loss narrows to $(0.41) from $(1.61)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $568.6M vs $543.1M YoY; GAAP gross margin 34% vs 31%.","GAAP net loss $(9.8)M ($(0.41)/diluted share) vs $(38.1)M ($(1.61)) a year ago.","Adjusted diluted EPS $1.74 (down from $1.82); adjusted EBITDA $102.0M vs $84.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":568649000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328243,"accession_number":"0000883984-23-000007","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q4 2022 revenue $578M, GAAP net loss $15.5M, provides FY23 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $578.0M vs $340.5M YoY; GAAP net loss $(15.5)M ($(0.65)/diluted) vs net income $19.9M ($0.91) in Q4 2021.","Adjusted diluted EPS $1.60 vs $1.82 YoY; adjusted EBITDA $96.4M vs $64.2M.","GAAP gross margin 30% vs 37% YoY; gross profit $174.9M vs $127.5M.","Fiscal year 2023 guidance announced but specific numbers not included in the excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":2279997000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328242,"accession_number":"0000883984-23-000003","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ICU Medical extends executive severance plan to Dec 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved Second Amendment to Executive Severance Plan on Dec 30, 2022.","Plan expiration date extended three years from Dec 31, 2022 to Dec 31, 2025.","Plan automatically terminates if no Change in Control occurs by Dec 31, 2025.","Amendment effective immediately; all other terms of the Plan unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345905,"accession_number":"0000883984-22-000044","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q3 2022 revenue $597.9M; GAAP loss $(0.55)/share; adj EPS $1.75","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $597.9M vs $336.1M YoY (+78%); GAAP net loss $(13.2)M ($(0.55)/diluted share).","Adjusted diluted EPS $1.75 vs $2.07 YoY; adjusted EBITDA $92.6M vs $71.9M.","GAAP gross margin 31% vs 38% YoY; gross profit $186.4M vs $127.8M.","Reaffirmed fiscal year 2022 guidance; no specific guidance numbers provided."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":1701983000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":362321,"accession_number":"0000883984-22-000039","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q2 revenue $561M; GAAP net loss $7.5M, adj EPS $1.37; updates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $561.0M vs $321.7M YoY; GAAP net loss $(7.5M) vs income $28.4M.","Adjusted diluted EPS $1.37 vs $1.88 YoY; Adjusted EBITDA $84.7M vs $66.9M.","GAAP gross margin fell to 30% from 38% YoY.","Company updated FY 2022 guidance; specific figures not provided in excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":1104126000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381861,"accession_number":"0000883984-22-000032","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2022-05-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ICU Medical shareholders elect all 9 director nominees and ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 9 director nominees elected; David F. Hoffmeister received most withheld votes (1,503,487) but was elected.","Appointment of Deloitte & Touche as independent auditor for FY2022 ratified: 21,245,122 for, 901,415 against.","Advisory vote on named executive officer compensation approved: 21,178,194 for, 200,369 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381860,"accession_number":"0000883984-22-000029","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q1 revenue $543M, GAAP net loss $38.1M, adjusted EPS $1.82","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $543.1M, up 71% from $318.0M in Q1 2021.","GAAP net loss of $38.1M ($1.61 per diluted share) vs net income of $23.7M ($1.09) in Q1 2021.","Adjusted diluted EPS $1.82, up from $1.62; adjusted EBITDA $84.9M vs $57.8M.","GAAP gross margin declined to 31% from 35% in Q1 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":543122000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381859,"accession_number":"0000883984-22-000026","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2022-04-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ICU Medical amends CEO Vivek Jain's contract: base salary $775K, enhanced equity vesting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Jain's base salary to $775,000 under amended employment agreement effective March 1, 2022 through March 2025.","Upon involuntary termination, equity awards granted Jan 2020-Dec 2021 vest fully (performance at target).","For termination near a change in control (60 days before to 2 years after), all time-based equity awards vest in full.","Agreement term until March 1, 2025, with automatic one-year renewals unless 60 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399818,"accession_number":"0000883984-22-000020","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K/A","filed_at":"2022-03-21T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"ICU Medical files Smiths Medical FY2021 audited financials; operating profit down 88% to $16M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Smiths Medical revenue $1,153M in FY2021, flat vs $1,159M prior year.","Operating profit fell to $16M from $129M; includes $83M impairment charge.","Net profit $66M vs $173M prior year; net assets $1,719M.","Acquisition closed Jan 6, 2022 for $1.9B cash, 2.5M ICU shares, and up to $100M earn-out."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399823,"accession_number":"0000883984-22-000012","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q4 2021 revenue up 6% to $340.5M; GAAP EPS drops to $0.91 from $1.21","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $340.5M vs $320.5M YoY; GAAP net income $19.9M ($0.91 diluted EPS) vs $26.1M ($1.21).","Adjusted diluted EPS $1.82 vs $1.77; adjusted EBITDA $64.2M vs $59.8M.","GAAP gross margin unchanged at 37%; FY2022 guidance provided in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":4.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":1316308000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399822,"accession_number":"0000883984-22-000009","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2022-02-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ICU Medical CAO Kevin McGrody to retire effective March 18, 2022; CFO Bonnell to assume duties","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CAO Kevin McGrody, 63, retiring effective March 18, 2022.","Search for successor commenced; CFO Brian Bonnell will assume CAO responsibilities in interim.","Bonnell currently serves as CFO; details in 10-K filed Feb 26, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399821,"accession_number":"0000883984-22-000007","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2022-02-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ICU Medical appoints William Seeger to Board; board expands to 9 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Seeger appointed to Board effective Feb 1, 2022; board expanded from 8 to 9.","Seeger designated by Smiths pursuant to Shareholders Agreement from Jan 6 acquisition of Smiths Medical.","Seeger will serve on Audit and Compliance Committee; no director compensation from ICU Medical.","Seeger will stand for election at the 2022 Annual Meeting expected in May 2022.","Standard indemnification agreement entered with Seeger per Delaware law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399820,"accession_number":"0000883984-22-000005","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2022-01-07T23:59:59+00:00","items":["1.01","2.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"ICU Medical completes acquisition of Smiths Medical for $1.85B cash + stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Paid $1.85B cash and issued 2.5M shares of ICUI common stock; up to $100M additional contingent cash.","Entered into $2.2B Credit Facilities: $850M Term Loan A, $850M Term Loan B, $500M revolver.","Pro forma combined revenue approximately $2.5 billion; Smiths adds infusion, vascular, vital care products.","Seller (Smiths Group) gets board seat if owns >5% of ICUI; share transfer restricted for 6 months.","Company plans to provide full FY 2022 guidance on Q4 earnings call in late February."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399819,"accession_number":"0000883984-22-000002","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2022-01-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ICU Medical board: Swinney retires after 24 years; Kennedy appointed independent director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Swinney retired from ICU Medical's board on Dec 31, 2021 after 24 years; no disagreement.","Kolleen Kennedy elected independent director effective Dec 31, 2021; will stand for election at 2022 annual meeting.","Kennedy previously served as President, Proton Solutions & Growth Office at Varian Medical Systems until Dec 31, 2021.","Kennedy receives prorated $170K annual equity award and $70K cash retainer as non-employee director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418804,"accession_number":"0000883984-21-000031","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q3 revenue $336.1M (+5.5% YoY); adj. EPS $2.07 vs $1.90","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $336.1M, up from $318.6M in Q3 2020.","GAAP net income $31.1M ($1.43 diluted) vs $25.0M ($1.16) YoY.","Adjusted diluted EPS $2.07 vs $1.90 in prior-year quarter.","Adjusted EBITDA $71.9M, compared to $62.2M in Q3 2020.","GAAP gross margin improved to 38% from 36% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":3.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":975783000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436390,"accession_number":"0000883984-21-000029","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2021-09-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ICU Medical enters binding agreement to acquire Smiths Medical after put option exercised","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Seller exercised put option on Sep 27, 2021, triggering binding purchase agreement for Smiths Medical.","ICU Medical commits to acquire Smiths Medical 2020 Limited, the holding company of Smiths Group's medical device business.","Form of Purchase Agreement previously filed as Exhibit 2.1 to Sep 8, 2021 8-K; no new financial terms disclosed.","Transaction subject to terms and conditions of the Purchase Agreement; closing conditions remain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436389,"accession_number":"0001193125-21-267387","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2021-09-08T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"ICU Medical to acquire Smiths Medical for $2.35B in cash and stock; expected close H1 2022","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration: $1.85B cash, 2.5M ICUI shares (~$500M), plus up to $100M earn-out based on stock price.","Combination creates ~$2.5B pro forma revenue infusion therapy company; Smiths to own ~10% of ICUI post-close.","Smiths gains board seat if it holds ≥5% of ICUI; shares subject to 6-month lock-up and standstill restrictions.","Transaction subject to antitrust, FDI approvals, and Smiths' French works council consultation; long-stop date undefined.","$2B senior secured credit facilities committed by Wells Fargo and Barclays to fund cash portion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436388,"accession_number":"0000883984-21-000027","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2021-08-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ICU Medical wins arbitration; Pfizer not entitled to up to $225M earn-out from 2017 Hospira deal","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Arbitrator ruled on August 7, 2021 that performance targets for HIS earn-out liability were not met.","Pfizer disputed ICU Medical's determination that the $191.3M to $225.0M earn-out was not payable.","Pfizer received no payment in connection with the earn-out liability under the Restated Purchase Agreement.","The dispute arose from the January 2017 acquisition of Pfizer's Hospira Infusion Systems business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436387,"accession_number":"0000883984-21-000024","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ICU Medical Q2 revenue $321.7M (+6% YoY); adj. EPS $1.88 vs $1.65","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $28.4M ($1.31 diluted EPS) vs $18.9M ($0.88) a year ago.","Adjusted EBITDA of $66.9M, up from $58.1M in Q2 2020.","GAAP gross margin improved to 38% from 35% year-over-year.","Company updated FY 2021 guidance in the release."],"consensus_eps_estimate":null,"consensus_eps_actual":2.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":639723000.0,"consensus_period":"2021-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":436386,"accession_number":"0000883984-21-000020","cik":883984,"company_name":"ICU MEDICAL INC/DE","ticker":"ICUI","form_type":"8-K","filed_at":"2021-07-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ICU Medical elects Laurie Hernandez to board, increasing size to eight","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to eight directors; Hernandez elected effective July 1, 2021.","Hernandez is a retired healthcare executive with over 25 years at Baxter and Hospira.","She receives a prorated annual equity award of $170K aggregate and $70K cash retainer.","Determined independent under NASDAQ rules; will stand for election at 2022 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3457612661.1853004,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}